Vilar E, Scaltriti M, Balmaña J, Saura C, Guzman M, Arribas J, Baselga J, Tabernero J
Department of Medical Oncology and Laboratory of Oncology Research, Vall d'Hebron University Hospital, Barcelona, Spain.
Br J Cancer. 2008 Nov 18;99(10):1607-12. doi: 10.1038/sj.bjc.6604691. Epub 2008 Oct 21.
Around 15% of colorectal cancers (CRCs) show microsatellite instability (MSI) due to dysfunction of the mismatch repair system (MMR). As a consequence of this, MSI tumours tend to accumulate errors in mononucleotide repeats as those in genes implicated in repairing double-strand breaks (DSBs). Previous studies have shown that irinotecan (CPT-11), a chemotherapy agent inducing DSB, is more active in MSI than in microsatellite stable (MSS) CRC. The purpose of this study was to compare the sensitivity to CPT-11 in a series of CRC cell lines with either proficient or deficient MMR and to assess the mutational status of two DSB repair genes, MRE11 and RAD50, in these cell lines. hMLH1-deficient cell lines due to either epigenetic silencing or mutation showed very similar IC(50) and were four- to nine-fold more sensitive to CPT-11 than the MSS line. Cell lines harbouring mutations in both MRE11 and RAD50 were most sensitive to CPT-11. We conclude that MSI cell lines display higher sensitivity to CPT-11 than MSS cells. Mutation of MRE11 and RAD50 could account for this difference in response to CPT-11. Future clinical trials tailoring chemotherapy regimens based on microsatellite status are warranted.
约15%的结直肠癌(CRC)由于错配修复系统(MMR)功能障碍而表现出微卫星不稳定性(MSI)。因此,MSI肿瘤倾向于在单核苷酸重复序列中积累错误,就像在参与修复双链断裂(DSB)的基因中那样。先前的研究表明,伊立替康(CPT-11)作为一种诱导DSB的化疗药物,在MSI CRC中比在微卫星稳定(MSS)CRC中更具活性。本研究的目的是比较一系列具有MMR功能正常或缺陷的CRC细胞系对CPT-11的敏感性,并评估这些细胞系中两个DSB修复基因MRE11和RAD50的突变状态。由于表观遗传沉默或突变导致hMLH1缺陷的细胞系表现出非常相似的半数抑制浓度(IC50),并且对CPT-11的敏感性比MSS细胞系高4至9倍。同时携带MRE11和RAD50突变的细胞系对CPT-11最为敏感。我们得出结论,MSI细胞系对CPT-11的敏感性高于MSS细胞。MRE11和RAD50的突变可能解释了对CPT-11反应的这种差异。未来有必要开展基于微卫星状态定制化疗方案的临床试验。